Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX390 and Toripalimab in Recurrent or Metastatic Cervical Cancer
NCT07392060Phase 3Not yet recruiting
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Feb 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of WXFL10030390 in Cervical Cancer (CC), sponsored by Shanghai Jiatan Pharmatech. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
WXFL10030390
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07392060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392060.